Synlogic, Inc. is a clinical-stage biopharmaceutical company in the United States, developing synthetic biotic medicines for the treatment of metabolic and immunological diseases. Its therapeutic programs include orally administered drug candidates for the treatment of phenylketonuria, homocystinuria, and enteric hyperoxaluria. The company is also developing an intratumorally administered synthetic biotic medicine for solid tumors and lymphoma.